Editor's note

This ExpertREACT article was originally published on 12 August 2008. ACIP recommendation details and market positions described reflect the state of knowledge at that date.

Extended recommendations: all children 5-18

Annual influenza vaccination is considered the most effective strategy for minimising influenza illness. The US ACIP's 2008-09 season recommendations continued to place primary focus on young children (6 months to 4 years) but now extended the recommendation to include all children aged 5-18 years. This expansion added many millions of children to the recommended population. The drivers were clear: during two consecutive US influenza seasons (2002-04), as high as one-third of all emergency department visits by children under five were due to laboratory-confirmed influenza illness. Annual influenza was responsible for approximately 36,000 deaths and 226,000 hospitalisations in the US between 1990 and 1999, with a disproportionate burden in the very young and elderly. Globally, the WHO estimated 250-500,000 deaths per season.

The dominant US seasonal influenza vaccine supplier was Sanofi Pasteur, which claimed greater than 50% US market share and was gearing up for what it anticipated would be a record season on the back of the expanded ACIP recommendations. For the 5-18 year group, both live attenuated (FluMist, Medimmune) and inactivated formulations were indicated. Novartis Vaccines' Fluvirin - an inactivated split-virion vaccine - was competing for paediatric doses, though its positioning in the 5-18 year group faced differentiation challenges relative to Sanofi's entrenched market presence and Medimmune's FluMist nasal spray appeal in children.

New ACIP influenza recommendation (2008-09)
All 5-18 yrs
Extension of routine influenza vaccination to all children and adolescents aged 5-18 years added millions to the recommended vaccination population

The commercial challenge of capturing new vaccinees

VacZine Analytics cautioned that translating the new ACIP recommendations into actual vaccination rates would not be straightforward. Coverage rates for the existing 6-month to 4-year recommendation were well below ideal, and establishing vaccine administration infrastructure for the newly included 5-18 year cohort - many of whom did not regularly see a paediatrician - would require school-based programme expansion and pharmacy network development. The focus on the 6-month to 4-year group particularly benefited Sanofi more than Novartis, as the FluZone paediatric formulation had a stronger historical positioning in the younger paediatric segment. Overall however, the direction of US ACIP recommendations pointed clearly toward annual universal influenza vaccination - a trajectory with very significant long-term commercial implications for all major flu vaccine suppliers.